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ABSTRACT
Background    Geraniol is a plant-derived phytochemi-
cal possessing anti-cancer action. The anti-carcinogenic 
effect of geraniol was investigated in the diethylnitrosa-
mine (DEN)-induced hepatocarcinogenic rat model.
Methods    Male Wistar rats were intraperitoneally in-
jected with 300 μL of phosphate-buffered saline (PBS) 
(G1; n = 4) or DEN (100 mg/kg body weight) dissolved 
in PBS (G2; n = 8) every 2 weeks on experimental 
weeks 2, 4 and 6. The rats were treated with a low con-
centration (0.07%) of geraniol (G3; n = 9) and high con-
centration (0.35%) of geraniol (G4; n = 7) for 12 weeks. 
To evaluate the effects of geraniol on the DEN-induced 
hepatocarcinogenesis, we compared the relative liver 
weight, serum aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT) and alkaline phosphatase 
(ALP) levels and expression levels of proliferating cell 
nuclear antigen (PCNA) and glutathione S transferase-P 
(GST-P) by immunohistochemical analyses among each 
group. 
Results    Relative liver weight was significantly higher 
in G2 than in G1 (P < 0.01). Both serum AST and ALT 
levels were significantly higher in G2 than in G3 and in 
G4 (P < 0.05). Serum ALP levels did not show a signifi-
cant difference among each group. Percentages of both 
PCNA- and GST-P- positive area were significantly de-
creased in G3 and in G4 compared to in G2 (P < 0.001, 
respectively), suggesting anti-hepatocarcinogenic effects 
of geraniol. 
Conclusion    Geraniol is a promising compound useful 
for suppression of hepatocellular carcinoma. The mecha-
nisms of action are required to be clarified in the future 
intensive study.
Key words    diethylnitrosamine; geraniol; hepatocellu-
lar carcinoma
Hepatocellular carcinoma (HCC) is one of the most 
common malignancies in Japan, responsible for over 
thirty thousand deaths per year.1  Diagnostic imaging for 
HCC in its early stage has progressed including contrast-
enhanced ultrasound and gadolinium ethoxybenzyl 
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diethylenetriamine pentaacetic acid (Gd-EOB) MRI. 
Therapeutic options for HCC including radiofrequency 
ablation (RFA), transcatheter arterial chemoemboliza-
tion (TACE), surgical resection and molecular-targeted 
therapy (Sorafenib), have also increased. Despite these 
advances in diagnosis and treatment, the prognosis of 
patients with HCC remains unsatisfactory.2 In order to 
improve the outcomes of patients with HCC, novel che-
mopreventive and therapeutic compounds are urgently 
required.
 Geraniol is a natural acyclic monoterpene contained 
in the essential oils of many aromatic plants such as 
geranium and lemon.3 It is widely used as an aromatic 
component in many cosmetic products. In addition to 
its aromatic properties, geraniol has been reported to 
demonstrate anti-tumor activity in a variety of cancer 
cells including lung,4 pancreatic,5 colon6 and liver.7 The 
mechanisms of anti-cancer effects of geraniol include 
inhibition of angiogenesis3 and the mevalonate pathway,4 
modulation of the Ras-extracellular signal-regulated 
kinase (ERK) signaling pathway8 and inhibition of NF-
KB,9 then leading to the modulation of cellular prolifera-
tion and apoptosis. However, little is known about gera-
niol inhibiting hepatocarcinogenesis in vivo.
 Diethylnitrosamine (DEN) is an established hepa-
tocarcinogen in rats.10 DEN has been reported to induce 
hepatocarcinogenesis by alteration of the DNA structure, 
formation of alkyl DNA adducts and induction of chro-
mosomal aberrations and micronuclei in the liver.11 In 
the present study, we evaluated anti-hepatocarcinogenic 
effects of geraniol in DEN-induced hepatocarninogenic 
rats.
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MATERIALS AND METHODS
Chemicals
Geraniol and PBS were purchased from Cosmo Bio (To-
kyo, Japan). DEN was purchased from Sigma Aldrich 
(St. Louis, MO). Pentobarbital was obtained from Dai-
nippon Sumitomo Pharma (Osaka, Japan). Antibodies 
against proliferating cell nuclear antigen (PCNA) and 
glutathione S-transferase (GST)-P were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA) and Assay 
Designs (Ann Arbor, MI), respectively. 
Animals, treatments and tissue collection
Male Wistar rats weighing 200 g or less were purchased 
from Japan SLC. (Hamamatsu, Japan). The rats were 
randomized, divided into four groups and were housed 
two per cage with rice husks for bedding in an air‑ven-
tilated room under a 12‑h light/dark cycle. In the animal 
room, the temperature (22 ˚C) and humidity (55%) were 
kept constant. The animals were allowed free access to 
food and tap water ad libitum during the experiment. 
All animals received humane care and protocols were 
approved by the Animal Ethics Committee of Tottori 
University (approval number 13-Y-35).
 As a control group, animals in group 1 (G1) were 
intraperitoneally injected with 300 μL of PBS (n = 4) 
every 2 weeks on experimental weeks 2, 4 and 6. In 
order to generate a hepatocarcinogenic model, animals 
in groups 2 (G2, n = 8), 3 (G3, n = 9) and 4 (G4, n = 7) 
were intraperitoneally injected with DEN (100 mg/kg 
body weight) dissolved in PBS every 2 weeks on experi-
mental weeks 2, 4 and 6. In order to examine the anti-
cancer effects of geraniol on the liver, the rats in group 3 
and 4 were fed with 0.07% and 0.35% geraniol in liquid 
form, respectively during the experimental period (Fig. 
1).
 One week subsequent to the final treatments, the an-
imals were sacrificed under anesthesia using pentobar-
bital. Blood samples were collected via cardiac puncture 
and serum samples were stored at –30 ˚C until analysis. 
Immediately following the excision of the livers, the 
livers were weighed and portions of the samples were 
stored in 10% neutral buffered formalin for histological 
examination.
Measurement of serum transaminase and alkaline 
phosphatase levels
Serum aspartate aminotransferase (AST), alanine ami-
notransferase (ALT) and alkaline phosphatase (ALP) 
levels were measured at SRL. (Tokyo, Japan).
Histology and immunohistochemistry
The rat liver tissues embedded in paraffin were stained 
with hematoxylin and eosin. For immunohistochem-
istry with the PCNA and GST-P antibodies, Histofine 
Simple Stain Rat MAX PO was employed (Nichirei 
Biosciences, Tokyo, Japan). Briefly, after routine dewax-
ing with xylene and hydration through a graded ethanol 
series, the sections were incubated with 1.5% hydrogen 
peroxide solution for 15 min at room temperature to 
quench endogenous peroxidase activity. The sections 
were washed in PBS, blocked with 1.5% serum solution 
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Figure 1	Fig. 1. Experimental schedules.
Animals in group 1 (G1) were intraperitoneally injected with 300 
μL of PBS (n =4) once every 2 weeks on experimental weeks 2, 4 
and 6. Animals in groups 2 (G2, n = 8), 3 (G3, n = 9) and 4 (G4, n 
= 7) were intraperitoneally injected with DEN (100 mg/kg body 
weight) dissolved in PBS once every 2 weeks on experimental 
weeks 2, 4 and 6. The animals in group 3 and 4 were treated with 
0.07% and 0.35% geraniol in liquid form, respectively, during 12 
weeks. DEN, diethylnitrosamine; PBS, phosphate-buffered saline.
Fig. 2. The relative liver weight compared among the groups (G1, 
G2, G3 and G4) demonstrated that the relative liver weight of the 
DEN groups (G2, G3 and G4) was significantly higher than that 
of the control group (G1). G1; PBS, G2; DEN, G3; DEN+0.07% 
geraniol, G4; DEN+0.35% geraniol.  **P < 0.01. DEN, diethylni-
trosamine; PBS, phosphate-buffered saline.
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and incubated with primary antibodies overnight at 4 
°C. After rinsing with PBS, the sections were incubated 
with biotinylated secondary antibody for 30 min at room 
temperature and horse HRP-conjugated ABC solution 
(Vector Laboratories, Burlingame, CA) was applied for 
30 min at room temperature. Peroxidase activity was 
developed with DAB solution (Vector Laboratories). 
Counterstaining was performed with hematoxylin. The 
PCNA labeling indices were represented as the percent-
age of positively stained nuclei by counting 1000 cells in 
a field at x200 magnification. The GST-P-positive area 
was measured on images captured by a Charge Coupled 
Device (CCD) camera on a Windows computer.
Statistical analysis
Values are expressed as mean ± SD. Means were com-
pared using the Student t-test. Statistical significance 
was inferred at P < 0.05.
RESULTS
Relative liver weight and serum liver enzyme levels
The relative liver weight (liver weight/body weight) was 
significantly higher in the DEN groups (G2, G3 and G4) 
than in the control group (G1) (Fig. 2, P<0.01), presum-
ably due to the development of liver tumors. Among the 
DEN groups G2, G3 and G4, the relative liver weight 
did not show a significant difference. Both serum trans-
aminases (AST and ALT) were significantly higher in 
the DEN administration group G2 than in the geraniol 
treatment groups G3 and G4 (P < 0.05, Figs. 3A and B). 
Serum ALP levels did not show significant differences 
among the DEN groups G2, G3 and G4 (Fig. 3C). These 
data suggest that both low (0.07%) and high (0.35%) 
concentrations of geraniol attenuated the liver injury and 
hepatic tumor formation.
Fig. 3. Serum AST (A), ALT (B) and ALP (C) levels compared 
among the groups (G1, G2, G3 and G4) demonstrated that serum 
transaminase levels were significantly higher in the DEN adminis-
tration group G2 than in the geraniol treatment groups G3 and G4 
(P < 0.05) and that serum ALP levels did not show any significant 
differences among the DEN groups G2, G3 and G4. *P < 0.05. 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; DEN, diethylnitrosamine.
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Macroscopic and histological examinations
Macroscopic and microscopic features of the liver were 
evaluated. As expected, in the liver of control rats (G1), 
no tumors were observed (Figs. 4A and B). Multiple 
white tumor formation was macroscopically observed in 
the DEN groups G2, G3 and G4 (Fig. 4A, arrows). 
 In the histological analysis, the white nodules in-
duced by DEN were hyperplastic nodules (Fig. 4B). 
Expression levels of PCNA and GST-P
PCNA is an essential regulator of the cell cycle and its 
expression is a useful tool for the study of cell prolifera-
tion.12 Among the glutathione S-transferases (GSTs), a 
family of detoxification enzymes catalyzing the conjuga-
40
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Figure 4B	Fig. 4. Representative macroscopic (A) and microscopic (B) features of the liver in the four groups (G1, G2, G3 and G4) demonstrated that 
no tumors were observed in the liver of control rats (G1) and that multiple white tumor formation was macroscopically observed in the 
DEN groups G2, G3 and G4. In the histological analysis, the white nodules induced by DEN were hyperplastic nodules (hematoxylin and 
eosin staining, Bars express 100 µm). Arrows indicate the representative nodules. DEN, diethylnitrosamine.
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tion of glutathione with a large number of carcinogens, 
placental GST (GST-P) is specifi cally expressed during 
rat hepatocarcinogenesis.13
 In order to confi rm the anti-tumor effects of gera-
niol, we evaluated the expression levels of PCNA and 
GST-P by immunohistochemical analyses. Immunos-
taining with the PCNA (Fig. 5) and GST-P (Fig. 6) 
antibodies revealed that no positive cells or areas were 
observed in the control livers (Figs. 5 and 6, G1). Ad-
ministration of DEN induced the nuclear expression of 
PCNA (Fig. 5, G2). Treatment with both low (0.07%) 
and high (0.35%) concentrations of geraniol signifi cantly 
attenuated the percentages of PCNA-positive cells in G3 
and G4 compared to G2 (Fig. 5, P < 0.001).
 Immunostaining with the GST-P antibody revealed 
mostly similar results as PCNA. Administration of DEN 
induced the appearance of a GST-P-positive area (Fig. 
6, G2). The GST-P-positive area was significantly de-
creased in G3 and G4 compared to G2 (Fig. 6, P < 0.001), 
although there was no signifi cant difference between G3 
and G4. These results indicate that geraniol could be a 
potent compound useful for the prevention of HCC.
DISCUSSION
HCC is the third-leading cause of death from cancer 
and the fi fth most prevalent malignancy worldwide.14,15 
Since most HCC is complicated with diseased liver in-
cluding chronic hepatitis and liver cirrhosis secondary 
to infection with hepatitis B virus (HBV), hepatitis C 
virus (HCV) and alcohol, regular surveillance of these 
patients who are at high risk of HCC by serum tumor 
markers and imaging has been conducted in Japan.16 
However, the prognosis of patients with HCC remains 
poor because HCC is often diagnosed at advanced 
stages due to the ineffi ciency of ultrasonography instru-
ment operators, dropout among the patients targeted by 
the screening program17 and the presence of a number of 
undiagnosed carriers of HBV and HCV18 which are dif-
fi cult to include in the screening program. Thus, novel 
preventive and therapeutic approaches for these patients 
are urgently required.
 Geraniol is an isoprenic derivative contained in the 
essential oils of many aromatic plants such as geranium 
and lemon.3 Beside its cosmetic use, geraniol has been 
demonstrated to have some bioactive properties includ-
ing anti-inflammation,19 anti-angiogenesis3 and anti-
tumor effects.5 Anti-tumor effects of geraniol have been 
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Fig. 5. Expression levels of PCNA examined by immunohisto-
chemical analysis in the four groups (G1, G2, G3 and G4) dem-
onstrated that no positive cells were observed in the control livers 
and that administration of DEN induced the nuclear expression of 
PCNA (G2), which was signifi cantly attenuated by the treatment 
with both low (0.07%, G3) and high (0.35%, G4) concentrations 
of geraniol. ***P < 0.001. Bars express 200 µm. Arrows indicate 
representative PCNA-positive nuclei. DEN, diethylnitrosamine．
PCNA, proliferating cell nuclear antigen. 
Fig. 6. Expression levels of GST-P examined by immunohisto-
chemical analysis in the four groups (G1, G2, G3 and G4) dem-
onstrated that no positive area was observed in the control livers 
and that administration of DEN induced GST-P-positive area 
(G2), which was signifi cantly inhibited by the treatment with both 
low (0.07%, G3) and high (0.35%, G4) concentrations of geraniol, 
revealing no signifi cant difference between G3 and G4. ***P < 
0.001. Bars express 200 µm. Arrows indicate representative GST-
P-positive area. DEN, diethylnitrosamine; GST-P, glutathione S 
transferase-P. 
42
S. Sawada et al.
demonstrated on a variety of cells including lung,4 pan-
creatic,5 colon6 and liver.7 In the liver, anti-tumor effects 
of geraniol have been demonstrated in culture cells7, 20 
and rats.21–23
 Thus geraniol is a promising candidate for the pre-
vention and therapy of HCC. However, the number of 
studies investigating the anti-tumor effects of geraniol 
on hepatocarcinogenesis is quite limited. Therefore, we 
sought to further examine the anti-hepatocarcinogenic 
effects of geraniol employing the DEN-induced he-
patocarcinogenic rat model which we have previously 
established.24–26 In the present study, we have dem-
onstrated that oral treatment by geraniol of the DEN-
induced hepatocarcinogenic rats significantly decreased 
serum transaminase levels and tumor formation of the 
liver based on the immunohistochemical analyses by 
the PCNA and GST-P antibodies. We determined the 
concentrations of geraniol based on a previous report.22 
However, appropriate concentrations of geraniol in hu-
mans need to be evaluated in future studies.
 In the current study, we did not explore the mecha-
nisms of antitumor action by geraniol. Although infor-
mation available is limited, induction of apoptosis was 
involved in the anti-proliferative effects of geraniol in 
rats.21, 22 In general, the proposed mechanisms by which 
miscellaneous plant-derived chemicals exhibit anti-
tumor effects on the liver include cell cycle arrest, in-
duction of apoptosis and inhibition of angiogenesis.27 It 
is conceivable that geraniol, a plant-derived compound, 
also modulated these cellular mechanisms. It is essen-
tial to investigate the modulation of signaling pathways 
which are relevant to the cell cycle, apoptosis and an-
giogenesis in DEN-administered rats after treating them 
with geraniol in future studies.
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